[Thoracic oncology and tumor mutational burden: Towards new challenges for the pathologist?]

[Thoracic oncology and tumor mutational burden: Towards new challenges for the pathologist?]

Ann Pathol. 2019 Jan 30;:

Authors: Hofman P

Abstract
Among the different promising predictive biomarkers in immuno-oncology, the tumor mutational burden (TMB) may soon impose itself in clinical routine practice, in association with PD-L1 immunohistochemistry testing. However, the TMB is used currently in clinical trials only, in particular in the thoracic oncology field. If this biomarker becomes mandatory in the near future, the pathologist will have to respond to new challenges in tight collaboration with the activity of molecular pathology platforms. Given the high incidence of lung cancer in France, this new development could have a strong impact on the daily life of the laboratories. This review addresses the different challenges which could be soon proposed to the laboratories and the pathologists due to the use of TMB assays on a daily practice.

PMID: 30711336 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader http://bit.ly/2BjGzf7